Skip to main navigation menu Skip to main content Skip to site footer

Vol. 13 No. 4 (2026)
International Multidisciplinary Journal for Research & Development

Articles

DAPAGLIFLOZIN AS PART OF COMBINATION THERAPY IN COPD COMORBID WITH HEART FAILURE: EFFECTS ON PULMONARY, CARDIAC, RENAL AND ENDOTHELIAL FUNCTION

Published 2026-04-03

  • Sulaymonov S.A., Nuriddinov N.N., Ochilov I.A.

Sulaymonov S.A., Nuriddinov N.N., Ochilov I.A.
Tashkent State Medical University, Tashkent, Republic of Uzbekistan

Abstract

SGLT2 inhibitors (iSGLT2) have demonstrated cardioprotective and nephroprotective benefits in heart failure (HF) and chronic kidney disease, but evidence in chronic obstructive pulmonary disease (COPD) comorbid with HF is limited. Dapagliflozin may offer pleiotropic benefits across pulmonary, cardiac, renal and endothelial domains in this high-risk population.

Keywords

COPD; heart failure; dapagliflozin; SGLT2 inhibitors; FEV₁; LVEF; eGFR; cystatin-C; E-selectin; NT-proBNP; cardiorespiratory comorbidity; nephroprotection.

PDF

References

  1. Ruvuna L, Sood A. Epidemiology of Chronic Obstructive Pulmonary Disease. Clin Chest Med. 2020;41(3):315–327.
  2. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016. Lancet. 2017;390(10100):1211–1259.
  3. Axson EL, Ragutheeswaran K, Sundaram V et al. Hospitalisation and mortality in patients with comorbid COPD and heart failure: a systematic review and meta-analysis. Respir Res. 2020;21(1):54.
  4. McMurray JJV, Solomon SD, Inzucchi SE et al. (DAPA-HF). Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
  5. Packer M, Anker SD, Butler J et al. (EMPEROR-Reduced). Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424.
  6. Heerspink HJL, Stefánsson BV, Correa-Rotter R et al. (DAPA-CKD). Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446.
  7. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108–2117.
  8. Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors. JACC Basic Transl Sci. 2020;5(6):632–644.
  9. Wu JY, Hu KC, Liu MY et al. The clinical effectiveness of sodium-glucose co-transporter-2 inhibitors on prognosis of patients with chronic obstructive pulmonary disease and diabetes. Nat Commun. 2025;16(1):5478.
  10. Yen FS, Wei JC, Huang YH et al. SGLT-2 inhibitors and the risk of chronic obstructive pulmonary disease exacerbations and mortality in COPD patients. Ann Am Thorac Soc. 2025;22(6):846–854.
  11. Shabil M, Patil J, Satapathy P et al. Effect of SGLT-2 inhibitors on COPD exacerbations in individuals with type 2 diabetes: a meta-analysis and Bayesian sensitivity analysis. J Diabetes Investig. 2025;16(9):1670–1682.
  12. Yu Z, Gu B, Zhang J et al. Novel antidiabetic agents and the risk of respiratory diseases: a systematic review and meta-analysis of 27 randomized controlled trials. Front Med. 2026;12:1721311.
  13. Barr RG, Bluemke DA, Ahmed FS et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010;362(3):217–227.
  14. Andre S, Conde B, Fragoso E et al. COPD and cardiovascular disease. Pulmonology. 2019;25(3):168–176.
  15. Wanner C, Inzucchi SE, Lachin JM et al. (EMPA-REG OUTCOME). Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334.
  16. Rangaswami J, Bhalla V, Blair JEA et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies. Circulation. 2019;139(16):e840–e878.
  17. Gimbrone MA, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118(4):620–636.
  18. Xu S, Ilyas I, Little PJ et al. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies. Pharmacol Rev. 2021;73(3):924–967.
  19. McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726.
  20. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. 2024 Report. goldcopd.org.

Downloads

Download data is not yet available.